These authors contributed equally to this work.
Article first published online: 12 JUL 2012
Copyright © 2012 American Association for the Study of Liver Diseases
Volume 56, Issue 3, pages 861–872, September 2012
How to Cite
Lagaye, S., Shen, H., Saunier, B., Nascimbeni, M., Gaston, J., Bourdoncle, P., Hannoun, L., Massault, P.-P., Vallet-Pichard, A., Mallet, V. and Pol, S. (2012), Efficient replication of primary or culture hepatitis C virus isolates in human liver slices: A relevant ex vivo model of liver infection. Hepatology, 56: 861–872. doi: 10.1002/hep.25738
Potential conflict of interest: Nothing to report.
- Issue published online: 28 AUG 2012
- Article first published online: 12 JUL 2012
- Accepted manuscript online: 27 MAR 2012 12:00AM EST
- Manuscript Accepted: 13 MAR 2012
- Manuscript Received: 28 JUN 2011
- Institut National de la Santé et de la Recherche Médicale (INSERM, France)
- Institut National du Cancer (INCa, France)
- Centre National de la Recherche Scientifique (CNRS, France) and from Roche
The development of human cultured hepatitis C virus (HCV) replication-permissive hepatocarcinoma cell lines has provided important new virological tools to study the mechanisms of HCV infection; however, this experimental model remains distantly related to physiological and pathological conditions. Here, we report the development of a new ex vivo model using human adult liver slices culture, demonstrating, for the first time, the ability of primary isolates to undergo de novo viral replication with the production of high-titer infectious virus as well as Japanese fulminant hepatitis type 1, H77/C3, and Con1/C3. This experimental model was employed to demonstrate HCV neutralization or HCV inhibition, in a dose-dependent manner, either by cluster of differentiation 81 or envelope protein 2–specific antibodies or convalescent serum from a recovered HCV patient or by antiviral drugs. Conclusion: This new ex vivo model represents a powerful tool for studying the viral life cycle and dynamics of virus spread in native tissue and also allows one to evaluate the efficacy of new antiviral drugs. (HEPATOLOGY 2012;56:861–872)